These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 19465418

  • 1. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.
    Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A, Sonneveld P, European Myeloma Network.
    Ann Oncol; 2009 Aug; 20(8):1303-17. PubMed ID: 19465418
    [Abstract] [Full Text] [Related]

  • 2. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ, Mancini I.
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [Abstract] [Full Text] [Related]

  • 3. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
    Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, García-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BG, Roodman GD.
    J Clin Oncol; 2013 Jun 20; 31(18):2347-57. PubMed ID: 23690408
    [Abstract] [Full Text] [Related]

  • 4. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
    Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS, American Society of Clinical Oncology Bisphosphonates Expert Panel.
    J Clin Oncol; 2002 Sep 01; 20(17):3719-36. PubMed ID: 12202673
    [Abstract] [Full Text] [Related]

  • 5. Osteonecrosis of the Jaw After Bisphosphonates Treatment in Patients with Multiple Myeloma.
    Krstevska S, Stavric SG, Cevrevska L, Georgjievski B, Karanfilski O, Sotirova T, Balkanov T.
    Med Arch; 2015 Dec 01; 69(6):367-70. PubMed ID: 26843726
    [Abstract] [Full Text] [Related]

  • 6. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.
    Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B.
    Ann Oncol; 2008 Mar 01; 19(3):420-32. PubMed ID: 17906299
    [Abstract] [Full Text] [Related]

  • 7. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.
    Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K, American Society of Clinical Oncology.
    J Clin Oncol; 2007 Jun 10; 25(17):2464-72. PubMed ID: 17515569
    [Abstract] [Full Text] [Related]

  • 8. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.
    Cafro AM, Barbarano L, Nosari AM, D'Avanzo G, Nichelatti M, Bibas M, Gaglioti D, Taroni A, Riva F, Morra E, Andriani A.
    Clin Lymphoma Myeloma; 2008 Apr 10; 8(2):111-6. PubMed ID: 18501105
    [Abstract] [Full Text] [Related]

  • 9. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B.
    Cochrane Database Syst Rev; 2012 May 16; (5):CD003188. PubMed ID: 22592688
    [Abstract] [Full Text] [Related]

  • 10. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel.
    De Marinis F, Eberhardt W, Harper PG, Sureda BM, Nackaerts K, Soerensen JB, Syrigos K, Trédaniel J.
    J Thorac Oncol; 2009 Oct 16; 4(10):1280-8. PubMed ID: 19701109
    [Abstract] [Full Text] [Related]

  • 11. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
    Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG.
    J Clin Oncol; 2000 Mar 16; 18(6):1378-91. PubMed ID: 10715310
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Bisphosphonates for myeloma patients].
    Miwa A.
    Nihon Rinsho; 2007 Dec 16; 65(12):2315-37. PubMed ID: 18069279
    [Abstract] [Full Text] [Related]

  • 14. Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures.
    Catania G, Monaco F, Limberti G, Alessio M, De Martino I, Barile C, Fasciolo A, Baraldi A, Ladetto M, Fusco V.
    Dent J (Basel); 2016 Dec 01; 4(4):. PubMed ID: 29563487
    [Abstract] [Full Text] [Related]

  • 15. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates.
    Pavkovic M, Petrushevska G, Jovanovic R, Karanfilski O, Cevreska L, Stankovic S, Stojanovic A.
    Prilozi; 2010 Dec 01; 31(2):39-49. PubMed ID: 21258276
    [Abstract] [Full Text] [Related]

  • 16. A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives.
    Chatziravdeli V, Katsaras GN, Katsaras D, Doxani C, Stefanidis I, Zintzaras E.
    J Musculoskelet Neuronal Interact; 2022 Dec 01; 22(4):596-621. PubMed ID: 36458395
    [Abstract] [Full Text] [Related]

  • 17. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
    Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA.
    Mayo Clin Proc; 2006 Aug 01; 81(8):1047-53. PubMed ID: 16901028
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonates in multiple myeloma.
    Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A.
    Cochrane Database Syst Rev; 2001 Aug 01; (4):CD003188. PubMed ID: 11687178
    [Abstract] [Full Text] [Related]

  • 19. Review of current literature and implications of RANKL inhibitors for oral health care providers.
    Epstein MS, Ephros HD, Epstein JB.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec 01; 116(6):e437-42. PubMed ID: 22901640
    [Abstract] [Full Text] [Related]

  • 20. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.
    J Clin Oncol; 2005 Dec 01; 23(34):8580-7. PubMed ID: 16314620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.